Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 4, 2001, Pages 391-394

  Brandolese, R ^a   Scordo, M G ^a   Spina, E ^a   Gusella, M ^a   Padrini, R ^a  

^a Dipartimento Di Farmacologia E Anestesiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9 3; GENE PRODUCT; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ALLELISM; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG OVERDOSE; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HEAD INJURY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PRIORITY JOURNAL; SEIZURE;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CRANIOCEREBRAL TRAUMA; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALF-LIFE; HOMOZYGOTE; HUMANS; METABOLIC DETOXICATION, DRUG; MUTATION; OVERDOSE; PHENYTOIN; SEIZURES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0034748878     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.118868     Document Type: Article

References (16)

1. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
2. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
3. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
4. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
5. The effect of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
6. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily
7. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
8. Phenytoin: Pharmacogenetic polymorphism of 4′-hydroxylation
9. The role of the CYP2C9-Leu 359 allelic variant in tolbutamide polymorphism
10. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
11. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
12. CYP2C9 and CYP2C19 polymorphisms in the Italian population
13. Effect of CYP2C9 polymorphism on warfarin maintenance dose and plasma S:R ratio
14. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
15. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication